Sergey Terushkin, MD, FACS a board-certified bariatric and general surgeon specializing in advanced non-surgical weight-loss treatments
"We hope these findings will inspire future efforts to pursue the development of JAK inhibitors for this disease and represent a first rationally-selected treatment based on some exciting new scientific findings." The researchers have not so far observed any adverse effects of ruxolitinib in their small trial, Christiano said
Although treatments are usually effective for managing thyroid function, individual genetic, environmental, or lifestyle factors that affect disease outcome and/or response to therapy are generally ignored
Estimated reading time: 7 minutesI received my diagnosis of hypermobile EDS because of MCAS, which is probably not the usual route
in vitro experiments showed that SGK1 knockdown alleviated erastin-induced downregulation of Slc7a11, GPX4, GSH, and GSSG, while reducing lipid peroxidation, iron accumulation, and mitochondrial damage upregulation, suggesting that SGK1 modulates ferroptosis processes through inflammatory pathways in CHD (44)
.png)
